Non-inferiority efficacy trial of risperidone long-acting injection vs. olanzapine tablets

被引：0
|
作者：
Rabinowitz, J [1 ]
Khan, A [1 ]
Augustyns, I [1 ]
Ingham, M [1 ]
机构：
[1] Bar Ilan Univ, IL-52100 Ramat Gan, Israel
来源：
SCHIZOPHRENIA RESEARCH | 2006年 / 81卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：94 / 95
页数：2
相关论文
共 50 条
  • [31] Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD
    Bioulac, Stephanie
    Purper-Ouakil, Diane
    Ross, Tomas
    Blasco-Fontecilla, Hilario
    Prats, Marie
    Mayaud, Louis
    Brandeis, Daniel
    BMC PSYCHIATRY, 2019, 19 (1)
  • [32] Cost effectiveness analysis of long-acting risperidone injection compared with olanzapine and fluphenazine decanoate in patients with schizophrenia
    Baca, E
    Bobes, J
    Cañas, F
    Leal, C
    Salvador, L
    Rubio, M
    Magaz, S
    Badía, X
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S238 - S238
  • [33] Efficacy and safety of long-acting risperidone microspheres and risperidone oral tables
    Chue, P
    Eerdekens, M
    Augustyns, I
    Lachaux, B
    Molcan, P
    Eriksson, L
    Pretorius, H
    David, A
    SCHIZOPHRENIA RESEARCH, 2002, 53 (03) : 174 - 175
  • [34] Direct transition to long-acting risperidone: Long term efficacy
    Kissling, W
    Heres, S
    Lloyd, K
    Sacchetti, E
    Bouhours, P
    Medori, R
    Llorca, PM
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 87 - 87
  • [35] Efficacy and safety of a novel long-acting risperidone formulation
    Kane, J
    Eerdekens, M
    Keith, S
    Lesem, M
    Karcher, K
    Lindenmayer, JP
    EUROPEAN PSYCHIATRY, 2002, 17 : 193S - 193S
  • [36] Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
    Takekita, Yoshiteru
    Koshikawa, Yosuke
    Fabbri, Chiara
    Sakai, Shiho
    Sunada, Naotaka
    Onohara, Ai
    Nishida, Keiichiro
    Yoshimura, Masafumi
    Kato, Masaki
    Serretti, Alessandro
    Kinoshita, Toshihiko
    BMC PSYCHIATRY, 2016, 16
  • [37] A study of the efficacy and safety of switching from oral risperidone to risperidone long-acting injection in older patients with schizophrenia
    Suzuki, Hidenobu
    Inoue, Yuichi
    Gen, Keishi
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2012, 2 (06) : 227 - 234
  • [38] Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
    Yoshiteru Takekita
    Yosuke Koshikawa
    Chiara Fabbri
    Shiho Sakai
    Naotaka Sunada
    Ai Onohara
    Keiichiro Nishida
    Masafumi Yoshimura
    Masaki Kato
    Alessandro Serretti
    Toshihiko Kinoshita
    BMC Psychiatry, 16
  • [39] Olanzapine concentrations collected postmortem in patients treated with olanzapine long-acting injection
    McDonnell, D. P.
    Detke, H. C.
    Falk, M.
    Shatapathy, C. C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S489 - S490
  • [40] COST OF LONG-ACTING RISPERIDONE INJECTION VERSUS LONG-ACTING PALIPERIDONE PALMITATE IN PATIENTS WITH SCHIZOPHRENIA IN RUSSIA
    Omelyanovsky, V
    Avxentyeva, M.
    Ivakhnenko, O.
    Khailov, P.
    Tsfasman, F. M.
    Krysanov, I
    Zorin, N.
    VALUE IN HEALTH, 2012, 15 (07) : A338 - A338
12345